The International Waldenstroms Macroglobulinemia Foundation Inc

The International Waldenstrom's Macroglobulinemia Foundation(IWMF) is a registered 501 (c)(3) organization dedicated to supporting everyone affected by Waldenstrom's macroglobulinemia (WM).  We support our community through research, support, education, and advocacy. Waldenstrom's macroglobulinemia, also known as lymphoplasmacytic lymphoma (or LPL), is a rare form of non-Hodgkin's lymphoma with no known cure. Because less than 1,500 cases are diagnosed annually in the US, Waldenstrom's is considered an orphan disease, making it difficult for researchers to secure funding and for patients to connect with one another. That's where IWMF comes in.

Led by an all volunteer board with a seven person administrative staff headquartered in Sarasota, Florida, the IWMF is lean but powerful organization, and a force behind changes that have made an enormous impact on the understanding of WM and the prognosis for patients. Since 1994, IWMF has been a global force in helping promote research, spread awareness, and empower patients and caregivers. IWMF helped fund the rationale for using BTK inhibitors in WM which led to Ibrutinib being the first drug specifically approved for the treatment of WM.

As the organization continues to fund and encourage research towards a cure, IWMF member services help patients, caregivers, and medical professionals around the globe make more informed healthcare decisions and connect the WM community locally and internationally.

Join IWMF, and help support intelligent programs that change lives and empower patients. Visit iwmf.com to learn more.